All Videos

Societal CDMO subject matter experts explore trends in pharmaceutical drug development and highlight capabilities of the US-based pharmaceutical CDMO company.

Societal CDMO subject matter experts explore trends in pharmaceutical drug development and highlight capabilities of the US-based pharmaceutical CDMO company.

In this episode of Drug Digest, Pharmaceutical Technology editors discuss what happens in the manufacturing space from a CDMO and a cell/gene therapy perspective.

Kelly Doering, senior director at Aspen Technology, unpacks various strategies for holistic data integration into pharma operations.

Mason Ailstock, CEO of the Rowen Foundation, discusses incubators and their potential to promote innovation.

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured.

Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.

In this episode of Drug Digest, Pharmaceutical Technology editors discuss what happens in early phase development, the role of CDMOs, and highlight the benefits and challenges of the outsourcing process.

In this episode of Drug Digest, Pharmaceutical Technology editors discuss the advantages and savings that continuous manufacturing may offer as well as the very real obstacles that might make a fully continuous process not feasible, especially in biologics manufacturing.